AlphAIAlphAI — Financial news for AI agents
mugglehead.comSEP 252 min read$MRK

Merck, Daiichi withdraw ifinatamab FDA application

Merck (MRK) and Daiichi Sankyo (4568) withdrew a U.S. FDA application for their small cell lung cancer drug ifinatamab deruxtecan, citing insufficient data. The Phase 2 trial showed a 54.8% response rate at a higher dose. The companies continue a Phase 3 trial, nearing full enrollment, with no new filing timeline provided.

Original reporting
mugglehead.com
Published Sep 25, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 11:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck, Daiichi withdraw ifinatamab FDA application — source image
Source · mugglehead.com
Decision brief

The 30-second read

$MRKBearishLow
01

Why it matters

Regulatory withdrawal removes an accelerated approval pathway, potentially delaying market entry and affecting stock valuations.

02

Market read

Regulatory setback for a joint oncology drug candidate; modest negative impact on both companies' stocks.

03

What to watch

Continued enrollment in Phase 3 trials could lead to a future filing; competitors' approvals may shift focus.

Relevance 7/10Novelty 7/10Timing: post-market Friday

Background

Merck and Daiichi Sankyo jointly develop ifinatamab deruxtecan, a B7‑H3‑directed ADC, across multiple cancers.

Company-level read

Ticker impact

$MRKBearishMedium confidence
Context

Merck withdrew its accelerated FDA application for ifinatamab deruxtecan in small cell lung cancer.

Expected impact

Likely modest decline in MRK share price pending further trial data.

Evidence & confidence

Withdrawal signals regulatory hurdle; no immediate alternative catalyst disclosed.

Market effects

Sector

Setback for B7‑H3 antibody ADCs in oncology; may slow investor enthusiasm for similar candidates.

Regional

Minor impact on US and Japanese pharma markets; broader sector remains unchanged.

Global

Limited to investors tracking oncology pipeline developments.

Counterpoint

What could challenge this read

If the Phase 3 trial later shows strong efficacy, the withdrawal may be a temporary setback with upside potential.

Key entities

  • company
    Merck & Co., Inc.

    US pharmaceutical company, ticker MRK.

  • company
    Daiichi Sankyo Co., Ltd.

    Japanese pharmaceutical company, ticker 4568.T.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 26
$MRKHighAI 9/10

What Does Merck (MRK) FDA Approval In Advanced Kidney Cancer Mean?

Merck (MRK) and Eisai received FDA approval for Welireg plus Lenvima to treat advanced kidney cancer after prior immunotherapy. The approval is based on Phase 3 trial data. Merck, valued at $367.1b, aims to expand its oncology portfolio with this new regimen, positioning it against competitors like cabozantinib. Investors will watch how quickly the new treatment gains market share.

simplywall.st2 min
SEP 25
$MRKMedAI 8/10

Merck withdrew its lung cancer drug application. A phase 3 trial is still enrolling.

Merck and Daiichi Sankyo withdrew the Biologics License Application for ifinatamab deruxtecan in treating extensive-stage small cell lung cancer. The decision follows discussions with the FDA, but enrollment continues in a phase 3 trial. The drug is a B7-H3 directed antibody drug conjugate being jointly developed by the companies. Both firms expressed disappointment but remain committed to evaluating the drug's potential in other cancer types.

stocktitan.net2 min
SEP 25
$MRKMedAI 8/10

Merck (MRK) Withdraws I-DXd Biologics License Application for ES

Merck (MRK) withdrew its BLA for I-DXd in treating extensive-stage small cell lung cancer, citing insufficient data for accelerated approval. The company remains committed to ongoing clinical trials. MRK's dividend yield is 2.31% with a high payout ratio of 1.11, and its stock is 23.2% overvalued relative to its GF Value. The company has a GF Score of 83, reflecting strong profitability and growth but valuation concerns.

gurufocus.com2 min
SEP 25
$MRKHighAI 9/10

Merck, Daiichi Sankyo withdraw US application for lung cancer therapy

Merck and Daiichi Sankyo withdrew their US application for accelerated approval of their experimental lung cancer therapy, ifinatamab deruxtecan, after the FDA deemed the mid-stage clinical study data insufficient. The therapy was intended for treating extensive-stage small cell lung cancer in adults who had progressed after standard chemotherapy, according to the companies.

ksl.com2 min